The new agreement is IBM Watson Health’s second collaboration with Guerbert, following the companies’ initial partnership in July 2018 geared toward developing similar AI imaging software for liver cancer care.
Under the new program, IBM and Guerbert will work to develop a tool using AI to help detect, segment, characterize and monitor lesions over time. The AI solution for prostate cancer care will be compatible with most picture archiving and communication system visualization systems to enhance its integration with workflows of healthcare professionals.
The number of prostate MRIs increases by more than 10 percent each year, and a 2017 Lancet study showed that 27 percent of biopsies may be avoided and 18 percent of unseen cancers are detected by using multiparameter MRI.
“The main diagnostic challenge with prostate cancer lies in identifying cancers requiring rapid treatment and those requiring only active surveillance, while avoiding unnecessary biopsies,” said David Gruen, MD, CMO of Imaging at IBM Watson Health. “For this reason, optimal patient outcomes depend on the rapid and accurate diagnosis and treatments that AI technologies can potentially help provide.”
More articles on artificial intelligence:
Google CEO: Comprehensive AI regulations could restrict innovation
Google Health takes over DeepMind: 4 things to know
Geisinger taps Tempus to develop AI precision medicine tools
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
